The role of transcranial direct current stimulation in diminishing the risk of pneumonia in patients with dysphagia: A double-blinded randomized clinical trial.
Autor: | Farpour S; Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.; Geriatric Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.; Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran., Asadi-Shekaari M; Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran., Borhani-Haghighi A; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran., Farpour HR; Geriatric Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.; Bone and Joint Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.; Department of Physical Medicine and Rehabilitation, Shiraz University of Medical Sciences, Shiraz, Iran., Rostamihosseinkhani M; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.; Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. |
---|---|
Jazyk: | angličtina |
Zdroj: | Current journal of neurology [Curr J Neurol] 2023 Jul 06; Vol. 22 (3), pp. 155-161. |
DOI: | 10.18502/cjn.v22i3.13793 |
Abstrakt: | Background: Dysphagia can be a life-threatening issue for post-stroke patients, with aspiration pneumonia (AP) being a common risk. However, there is hope through the potential combination of transcranial direct current stimulation (tDCS) and classical behavior therapy. Our study aims to investigate the effectiveness of this combination in diminishing the risk of AP in patients with dysphagia who suffered from stroke. Methods: In this randomized, parallel-group, blinded clinical trial, 48 patients were allocated into the sham group (speech therapy + 30 seconds of tDCS) and the real group (speech therapy + 20 minutes of tDCS). We used the Mann Assessment of Swallowing Ability (MASA) as an assessment tool. We assessed patients at baseline, one day after treatment, and at a one-month follow-up. Results: Groups showed no significant difference at baseline. After treatment, the real group showed a significant difference in the severity risk of AP (P = 0.02); the same was for the follow-up (P = 0.04). The number of patients showing severe risk of AP was higher in the sham group after treatment (n = 13, 54.20%) and at follow-up (n = 4, 18.20%) than the real group (n = 4, 16.70%; n = 1, 4.50%, respectively). None of the patients reported the history of AP at any stage of assessment. Conclusion: Although the results were more promising in the real group than the sham group in reducing the risk of AP, both techniques can prevent AP. Therefore, we recommend early dysphagia management to prevent AP regardless of the treatment protocol. Competing Interests: The authors declare no conflict of interest in this study. (Copyright © 2023 Iranian Neurological Association, and Tehran University of Medical Sciences Published by Tehran University of Medical Sciences.) |
Databáze: | MEDLINE |
Externí odkaz: |